Anti-Covid drug developed by DRDO
- The Drugs Controller General of India (DCGI) has approved the emergency use of Drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderate to severe Covid-19 patients.
DEVELOPMENT
- The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
- In April 2020, during the first wave of the pandemic, INMAS-DRDO scientists conducted had laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad.
- It found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth.
- 2-DG, works by preventing the supply of glucose molecules to the cancerous cells, which need glucose for survival.
- With the drug stopping the glucose supply, the cells start dying.
- The drug comes in powder form in sachet, which is taken orally by dissolving it in water.
- It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production.
- Its selective accumulation in virally infected cells makes this drug unique.
Comments
Post a Comment